Cogent Biosciences (COGT) Price & Analysis

Compare

604 Followers

COGT Stock Chart & Stats

Day’s Range― - ―

52-Week Range$3.72 - $12.97

Previous CloseN/A

Volume181.15K

Average Volume (3M)3.94M

Market Cap

$1.53B

Enterprise Value$752.59M

Total Cash (Recent Filing)$237.85M

Total Debt (Recent Filing)$16.71M

Price to Earnings (P/E)―

Beta0.96

Next Earnings

Nov 17, 2025

EPS Estimate

-0.52

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.59

Shares Outstanding139,700,790

10 Day Avg. Volume1,755,902

30 Day Avg. Volume3,940,910

Financial Highlights & Ratios

PEG Ratio-1.92

Price to Book (P/B)3.16

Price to Sales (P/S)0.00

P/FCF Ratio-3.89

Enterprise Value/Market Cap0.49

Enterprise Value/Revenue175.35

Enterprise Value/Gross Profit717.44

Enterprise Value/Ebitda-2.59

Forecast

1Y Price Target

$19.82

Price Target Upside80.84% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering12

Bulls Say, Bears Say

Bulls Say

Clinical TrialsRecent top-line results for bezuclastinib’s SUMMIT trial in non-advanced systemic mastocytosis was well-received, propelling Cogent up 69%.

Financial PositionCogent ended with roughly $453M in pro forma cash and cash equivalents, which should provide an operational runway into 2027.

Market OpportunityBezuclastinib is not a one-trick pony for NonAdvSM and is considered a cleaner tyrosine kinase inhibitor that could work better in advanced systemic mastocytosis and oncologic indications like GIST.

Bears Say

Market SentimentShort interest is at 10.0% of the float, which could indicate some skepticism or bearish sentiment among investors.

Regulatory ConcernsThe company changed the timing guidance for PEAK readout to 2H25, generating questions from some investors who were concerned that the change may signal that the bezu arm may be underperforming.

Cogent Biosciences News

Cogent Biosciences price target lowered to $21 from $22 at H.C. Wainwright

H.C. Wainwright analyst Robert Burns lowered the firm’s price target on Cogent Biosciences (COGT) to $21 from $22...

4d ago

COGT

Cogent Biosciences reports Q2 net loss $73.529M vs $58.95M last year

“We were thrilled to announce bezuclastinib’s impressive performance in the SUMMIT trial, demonstrating clinically meaningful and statistically significant...

5d ago

COGT

Cogent Biosciences price target raised to $22 from $15 at Citi

Citi raised the firm’s price target on Cogent Biosciences (COGT) to $22 from $15 and keeps a Buy...

23d ago

BPMC

COGT

Cogent Biosciences Reports Increased Losses Amidst Ongoing Development

Cogent Biosciences, Inc. ( ($COGT) ) has released its Q2 earnings. Here is a breakdown of the information...

4d ago

COGT

Promising Pipeline and Financial Stability Drive Buy Rating for Cogent Biosciences

Cogent Biosciences, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sam Slutsky from...

4d ago

COGT

Promising Developments and Undervaluation Drive Buy Rating for Cogent Biosciences

Cogent Biosciences, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst David Lebowitz from...

23d ago

COGT

Cogent Biosciences: Buy Rating Affirmed Amid Promising Trials and Strategic Advantages

Leerink Partners analyst Andrew Berens maintained a Buy rating on Cogent Biosciences on July 14 and set a...

25d ago

COGT

Cogent Biosciences Raises $230M Through Stock Sale

An update from Cogent Biosciences ( ($COGT) ) is now available. On July 8, 2025, Cogent Biosciences entered...

1M ago

COGT

Cogent Biosciences 22.2M share Spot Secondary priced at $9.00

The deal size was increased to $200M from $150M and priced at low end of $9.00-$9.50 range. JPMorgan,...

1M ago

COGT

Cogent Biosciences $150M Spot Secondary; price range $9.00-$9.50

JPMorgan, Leerink and Guggenheim are acting as joint book running managers for the offering. Published first on TheFly...

1M ago

COGT

Cogent Biosciences offers to sell $150M in common stock

Cogent “intends to use the net proceeds from the offering for continued development, regulatory and commercial preparation activities...

1M ago

COGT

Cogent Biosciences price target raised to $22 from $12 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Cogent Biosciences (COGT) to $22 from $12 and keeps a...

1M ago

COGT

Cogent Biosciences price target raised to $9 from $7 at Baird

Baird analyst Colleen Kusy raised the firm’s price target on Cogent Biosciences (COGT) to $9 from $7 and...

1M ago

COGT

Promising Outlook for Cogent Biosciences: Bezuclastinib’s Potential in Systemic Mastocytosis and Beyond

In a report released today, Anupam Rama from J.P. Morgan maintained a Buy rating on Cogent Biosciences, with...

1M ago

COGT

COGT FAQ

What was Cogent Biosciences’s price range in the past 12 months?

Cogent Biosciences lowest stock price was $3.72 and its highest was $12.97 in the past 12 months.

What is Cogent Biosciences’s market cap?

Cogent Biosciences’s market cap is $1.53B.

When is Cogent Biosciences’s upcoming earnings report date?

Cogent Biosciences’s upcoming earnings report date is Nov 17, 2025 which is in 99 days.

How were Cogent Biosciences’s earnings last quarter?

Cogent Biosciences released its earnings results on Aug 05, 2025. The company reported -$0.588 earnings per share for the quarter, missing the consensus estimate of -$0.583 by -$0.005.

Is Cogent Biosciences overvalued?

According to Wall Street analysts Cogent Biosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Cogent Biosciences pay dividends?

Cogent Biosciences does not currently pay dividends.

What is Cogent Biosciences’s EPS estimate?

Cogent Biosciences’s EPS estimate is -0.52.

How many shares outstanding does Cogent Biosciences have?

Cogent Biosciences has 139,700,790 shares outstanding.

What happened to Cogent Biosciences’s price movement after its last earnings report?

Cogent Biosciences reported an EPS of -$0.588 in its last earnings report, missing expectations of -$0.583. Following the earnings report the stock price went down -5.726%.

Which hedge fund is a major shareholder of Cogent Biosciences?

Currently, no hedge funds are holding shares in COGT

Cogent Biosciences Stock Smart Score

Outperform

Fundamentals

Return on Equity

-107.55%

Trailing 12-Months

Asset Growth

-36.08%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Cogent Biosciences

Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies to treat genetically driven diseases. The company operates primarily in the biopharmaceutical sector and is dedicated to advancing its core product pipeline, which includes experimental therapies for specific genetic mutations linked to rare disorders and cancers. Cogent Biosciences aims to address unmet medical needs through targeted treatment options, leveraging its expertise in genetic and molecular biology.

Cogent Biosciences (COGT) Earnings & Revenues

Historic Earnings Reports

COGT Stock 12 Month Forecast

Average Price Target

$19.82

▲(80.84% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","31":"$31","10.75":"$10.75","17.5":"$17.5","24.25":"$24.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.82,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$19.82</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,10.75,17.5,24.25,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.4,12.830769230769231,14.261538461538462,15.692307692307693,17.123076923076923,18.553846153846155,19.984615384615385,21.415384615384617,22.846153846153847,24.276923076923076,25.70769230769231,27.13846153846154,28.56923076923077,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.4,12.047692307692309,12.695384615384615,13.343076923076923,13.990769230769232,14.638461538461538,15.286153846153846,15.933846153846154,16.58153846153846,17.229230769230767,17.876923076923077,18.524615384615384,19.17230769230769,{"y":19.82,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.4,11.292307692307693,11.184615384615386,11.076923076923077,10.96923076923077,10.861538461538462,10.753846153846155,10.646153846153846,10.538461538461538,10.430769230769231,10.323076923076924,10.215384615384615,10.107692307692307,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.36,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.74,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.75,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.72,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.47,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.8,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.31,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.53,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.79,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.63,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.61,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.22,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.4,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >